董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dirk Thye | 男 | Chief Executive Officer, Chief Medical Officer and Director | 56 | 未披露 | 未持股 | 2026-01-30 |
| Christopher J. Senner | 男 | Director | 58 | 未披露 | 未持股 | 2026-01-30 |
| David Lamond | 男 | Director and Chairperson of the Board | 51 | 未披露 | 未持股 | 2026-01-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dirk Thye | 男 | Chief Executive Officer, Chief Medical Officer and Director | 56 | 未披露 | 未持股 | 2026-01-30 |
| Charles Ryan | 男 | President | 61 | 未披露 | 未持股 | 2026-01-30 |
| Charles Ryan | 男 | President | 60 | 未披露 | 未持股 | 2026-01-30 |
| Brendan Hannah | 男 | Chief Operating Officer, Chief Business Officer and Chief Compliance Officer | 40 | 未披露 | 未持股 | 2026-01-30 |
董事简历
中英对照 | 中文 | 英文- Dirk Thye
-
Dirk Thye，2014年7月加入本公司，担任首席医学官。2005年以来，他是生物制药私营公司Cerexa的创始人之一，该公司在2007年被Forest Laboratories, Inc收购。他在Forest Laboratories, Inc担任过一些职务，于2011年以总裁身份结束任职。加入Cerexa之前，2001-2005，他是生物制药公司Peninsula Pharmaceuticals的创始人、临床开发高级副总裁。另外，他曾在抗感染领域的一些公司担任董事或科学顾问委员会成员。他在University of California, Berkeley获得分子生物学士学位，在 University of California, Los Angeles获得医学博士学位，在Stanford University的内科完成驻院实习。
Dirk Thye was one of the founders of Cerexa, a private biopharmaceutical company that was acquired in 2007 by Forest Laboratories, Inc. Dr. Thye held a number of positions at Forest Laboratories and completed his tenure there in 2011 as President. Prior to joining Cerexa, Dr. Thye was a founder and Senior Vice President of Clinical Development for Peninsula Pharmaceuticals, a biopharmaceutical company, from 2001 until 2005. In addition, Dr. Thye has served as a member of the board of directors or scientific advisory board member for a number of companies in the anti-infective area, and currently serves as a director of Kalyra Pharmaceuticals, Inc., a private biopharmaceutical company. Dr. Thye received his B.A. in Molecular Biology from University of California, Berkeley, his M.D. from University of California, Los Angeles, and completed his residency in Internal Medicine at Stanford University. - Dirk Thye，2014年7月加入本公司，担任首席医学官。2005年以来，他是生物制药私营公司Cerexa的创始人之一，该公司在2007年被Forest Laboratories, Inc收购。他在Forest Laboratories, Inc担任过一些职务，于2011年以总裁身份结束任职。加入Cerexa之前，2001-2005，他是生物制药公司Peninsula Pharmaceuticals的创始人、临床开发高级副总裁。另外，他曾在抗感染领域的一些公司担任董事或科学顾问委员会成员。他在University of California, Berkeley获得分子生物学士学位，在 University of California, Los Angeles获得医学博士学位，在Stanford University的内科完成驻院实习。
- Dirk Thye was one of the founders of Cerexa, a private biopharmaceutical company that was acquired in 2007 by Forest Laboratories, Inc. Dr. Thye held a number of positions at Forest Laboratories and completed his tenure there in 2011 as President. Prior to joining Cerexa, Dr. Thye was a founder and Senior Vice President of Clinical Development for Peninsula Pharmaceuticals, a biopharmaceutical company, from 2001 until 2005. In addition, Dr. Thye has served as a member of the board of directors or scientific advisory board member for a number of companies in the anti-infective area, and currently serves as a director of Kalyra Pharmaceuticals, Inc., a private biopharmaceutical company. Dr. Thye received his B.A. in Molecular Biology from University of California, Berkeley, his M.D. from University of California, Los Angeles, and completed his residency in Internal Medicine at Stanford University.
- Christopher J. Senner
-
Christopher J. Senner， 曾一直担任执行副总裁兼首席财务官、首席财务官兼首席会计官（由适用的证券法定义）（2015年7月以来）。加入Exelixis公司之前，他曾担任Gilead Sciences, Inc.（生物制药公司）的公司财务副总裁（2010年3月至2015年7月），在那里他曾负责管理员职位、运营财务计划和分析，包括研发、制造、商业运作、税收和财政计划。他此前曾任职Wyeth公司18年，担任多种财务职务，并不断被提拔，最近担任Wyeth公司的美国制药企业和生物制药业务单元的首席财务官。他持有Bentley College的财务学士学位。此前披露指示他是一位注册会计师不准确是由于相关文件中的行政错误。他不是一个注册会计师。
Christopher J. Senner,served as Vice President, Corporate Finance for Gilead Sciences, Inc., a biopharmaceutical company, from 2010 to 2015, where he was accountable for controllership, tax, treasury and corporate and operational financial planning. Mr. Senner previously spent 18 years at Wyeth, a pharmaceutical company acquired by Pfizer Inc. in 2009, in a variety of financial roles with increasing responsibility, most notably as Chief Financial Officer of Wyeth's United States pharmaceuticals business and the BioPharma business unit. Mr. Senner holds an undergraduate degree in Finance from Bentley College. - Christopher J. Senner， 曾一直担任执行副总裁兼首席财务官、首席财务官兼首席会计官（由适用的证券法定义）（2015年7月以来）。加入Exelixis公司之前，他曾担任Gilead Sciences, Inc.（生物制药公司）的公司财务副总裁（2010年3月至2015年7月），在那里他曾负责管理员职位、运营财务计划和分析，包括研发、制造、商业运作、税收和财政计划。他此前曾任职Wyeth公司18年，担任多种财务职务，并不断被提拔，最近担任Wyeth公司的美国制药企业和生物制药业务单元的首席财务官。他持有Bentley College的财务学士学位。此前披露指示他是一位注册会计师不准确是由于相关文件中的行政错误。他不是一个注册会计师。
- Christopher J. Senner,served as Vice President, Corporate Finance for Gilead Sciences, Inc., a biopharmaceutical company, from 2010 to 2015, where he was accountable for controllership, tax, treasury and corporate and operational financial planning. Mr. Senner previously spent 18 years at Wyeth, a pharmaceutical company acquired by Pfizer Inc. in 2009, in a variety of financial roles with increasing responsibility, most notably as Chief Financial Officer of Wyeth's United States pharmaceuticals business and the BioPharma business unit. Mr. Senner holds an undergraduate degree in Finance from Bentley College.
- David Lamond
-
David Lamond自2020年2月以来一直担任我们的董事会成员。自2016年4月起，Lamond先生一直担任投资公司En Pointe LLC的总裁。2011年11月至2016年6月，他担任对冲基金Lamond Capital Partners LLC的总裁，首席执行官和首席投资官。他自2018年9月起担任生物技术公司Applied Molecular TransportInc.的董事会成员，自2020年2月起担任医疗器械公司Inquis Clinical Research Ltd.的董事会成员，自2015年12月起担任生物制药公司Cortexyme，Inc.的董事会成员，自2015年12月起担任基因治疗公司Genelpis的董事会成员，自2019年8月起担任Arrinex，Inc.（一家医疗设备公司，现为史赛克公司的子公司）的董事会成员。Lamond先生拥有杜克大学（Duke University）历史学学士学位和杜克法学院（Duke Law School）法学博士学位。
David Lamond,serves on the board of directors of EG 427, a biotechnology company, Inquis Medical, a medical device company and Windfall Data, an analytics company. He previously served on the board of Applied Molecular Transport, a biotechnology company, and Arrinex, a medical device company until its acquisition by Stryker Corporation in February 2019. Mr. Lamond holds a B.A. in History from Duke University and a J.D. from Duke Law School. - David Lamond自2020年2月以来一直担任我们的董事会成员。自2016年4月起，Lamond先生一直担任投资公司En Pointe LLC的总裁。2011年11月至2016年6月，他担任对冲基金Lamond Capital Partners LLC的总裁，首席执行官和首席投资官。他自2018年9月起担任生物技术公司Applied Molecular TransportInc.的董事会成员，自2020年2月起担任医疗器械公司Inquis Clinical Research Ltd.的董事会成员，自2015年12月起担任生物制药公司Cortexyme，Inc.的董事会成员，自2015年12月起担任基因治疗公司Genelpis的董事会成员，自2019年8月起担任Arrinex，Inc.（一家医疗设备公司，现为史赛克公司的子公司）的董事会成员。Lamond先生拥有杜克大学（Duke University）历史学学士学位和杜克法学院（Duke Law School）法学博士学位。
- David Lamond,serves on the board of directors of EG 427, a biotechnology company, Inquis Medical, a medical device company and Windfall Data, an analytics company. He previously served on the board of Applied Molecular Transport, a biotechnology company, and Arrinex, a medical device company until its acquisition by Stryker Corporation in February 2019. Mr. Lamond holds a B.A. in History from Duke University and a J.D. from Duke Law School.
高管简历
中英对照 | 中文 | 英文- Dirk Thye
Dirk Thye，2014年7月加入本公司，担任首席医学官。2005年以来，他是生物制药私营公司Cerexa的创始人之一，该公司在2007年被Forest Laboratories, Inc收购。他在Forest Laboratories, Inc担任过一些职务，于2011年以总裁身份结束任职。加入Cerexa之前，2001-2005，他是生物制药公司Peninsula Pharmaceuticals的创始人、临床开发高级副总裁。另外，他曾在抗感染领域的一些公司担任董事或科学顾问委员会成员。他在University of California, Berkeley获得分子生物学士学位，在 University of California, Los Angeles获得医学博士学位，在Stanford University的内科完成驻院实习。
Dirk Thye was one of the founders of Cerexa, a private biopharmaceutical company that was acquired in 2007 by Forest Laboratories, Inc. Dr. Thye held a number of positions at Forest Laboratories and completed his tenure there in 2011 as President. Prior to joining Cerexa, Dr. Thye was a founder and Senior Vice President of Clinical Development for Peninsula Pharmaceuticals, a biopharmaceutical company, from 2001 until 2005. In addition, Dr. Thye has served as a member of the board of directors or scientific advisory board member for a number of companies in the anti-infective area, and currently serves as a director of Kalyra Pharmaceuticals, Inc., a private biopharmaceutical company. Dr. Thye received his B.A. in Molecular Biology from University of California, Berkeley, his M.D. from University of California, Los Angeles, and completed his residency in Internal Medicine at Stanford University.- Dirk Thye，2014年7月加入本公司，担任首席医学官。2005年以来，他是生物制药私营公司Cerexa的创始人之一，该公司在2007年被Forest Laboratories, Inc收购。他在Forest Laboratories, Inc担任过一些职务，于2011年以总裁身份结束任职。加入Cerexa之前，2001-2005，他是生物制药公司Peninsula Pharmaceuticals的创始人、临床开发高级副总裁。另外，他曾在抗感染领域的一些公司担任董事或科学顾问委员会成员。他在University of California, Berkeley获得分子生物学士学位，在 University of California, Los Angeles获得医学博士学位，在Stanford University的内科完成驻院实习。
- Dirk Thye was one of the founders of Cerexa, a private biopharmaceutical company that was acquired in 2007 by Forest Laboratories, Inc. Dr. Thye held a number of positions at Forest Laboratories and completed his tenure there in 2011 as President. Prior to joining Cerexa, Dr. Thye was a founder and Senior Vice President of Clinical Development for Peninsula Pharmaceuticals, a biopharmaceutical company, from 2001 until 2005. In addition, Dr. Thye has served as a member of the board of directors or scientific advisory board member for a number of companies in the anti-infective area, and currently serves as a director of Kalyra Pharmaceuticals, Inc., a private biopharmaceutical company. Dr. Thye received his B.A. in Molecular Biology from University of California, Berkeley, his M.D. from University of California, Los Angeles, and completed his residency in Internal Medicine at Stanford University.
- Charles Ryan
Charles Ryan目前担任生物技术后期公司Quince Therapeutics，Inc.（纳斯达克：QNCX）的总裁及其子公司Quince Therapeutics S.P.A.的首席执行官，自2023年9月起担任该职务。在加入Quince之前，Ryan博士在2022年11月至2023年9月期间担任生命科学顾问，与一家初创公司合作，确定一种新型设备的监管路径。Ryan博士于2021年5月至2022年10月担任生物制药公司Travecta Therapeutics，Pte Ltd.的总裁、首席执行官兼董事会主席，于2017年12月至2020年12月担任生物制药公司Neurotrope, Inc.（纳斯达克：NTRP）的首席执行官兼董事，并于2016年10月至2018年2月担任OrthoBond Corporation的总裁兼首席执行官。在其职业生涯的早期，Ryan博士曾在Forest Laboratories（现为艾伯维）担任高级副总裁兼首席知识产权法律顾问十多年。Ryan Previoly先生于2011年8月至2019年11月担任Applied DNA Sciences，Inc.（纳斯达克：APDN）的董事会成员，并于2015年4月至2020年1月担任BioRestorative Therapies，Inc.（纳斯达克：BRTX）的董事会成员。Ryan博士拥有斯特恩新英格兰大学法学博士学位、纽约州立大学石溪分校口腔生物学和病理学博士学位以及伍斯特学院化学学士学位。他是纽约州律师协会会员，是美国专利商标局的专利从业人员。
Charles Ryan has served as a member of Polaryx Therapeutics, Inc. Board since January 2026. Dr. Ryan currently serves as President of Quince Therapeutics, Inc. (Nasdaq: QNCX), a late stage biotechnology company, and Chief Executive Officer of their subsidiary company, Quince Therapeutics S.p.A, positions he has held since September 2023. Prior to joining Quince, Dr. Ryan served as a life sciences consultant from November 2022 to September 2023 working with a start up company to identify a regulatory path for a novel device. Dr. Ryan served as President, Chief Executive Officer and Chairman of the Board of Travecta Therapeutics, Pte Ltd., a biopharmaceutical company, from May 2021 to October 2022, and Chief Executive Officer and Director of Neurotrope, Inc. (Nasdaq: NTRP), a biopharmaceutical company, from December 2017 to December 2020 and President and Chief Executive Officer of Orthobond Corporation from October 2016 to February 2018. Earlier in his career, Dr. Ryan served as Senior Vice President and Chief Intellectual Property Counsel at Forest Laboratories (now AbbVie) for more than ten years. Mr. Ryan previoly served on the board of directors of Applied DNA Sciences, Inc. (Nasdaq: APDN) from Augt 2011 to November 2019 and BioRestorative Therapies, Inc. (Nasdaq: BRTX) from April 2015 to January 2020.Dr. Ryan holds a J.D. from stern New England University, a Ph.D. in Oral Biology and Pathology from the State University of New York at Stony Brook, and a B.A. in Chemistry from The College of Wooster. He is a member of the New York State Bar and is a patent practitioner of the U.S. Patent and Trademark Office.- Charles Ryan目前担任生物技术后期公司Quince Therapeutics，Inc.（纳斯达克：QNCX）的总裁及其子公司Quince Therapeutics S.P.A.的首席执行官，自2023年9月起担任该职务。在加入Quince之前，Ryan博士在2022年11月至2023年9月期间担任生命科学顾问，与一家初创公司合作，确定一种新型设备的监管路径。Ryan博士于2021年5月至2022年10月担任生物制药公司Travecta Therapeutics，Pte Ltd.的总裁、首席执行官兼董事会主席，于2017年12月至2020年12月担任生物制药公司Neurotrope, Inc.（纳斯达克：NTRP）的首席执行官兼董事，并于2016年10月至2018年2月担任OrthoBond Corporation的总裁兼首席执行官。在其职业生涯的早期，Ryan博士曾在Forest Laboratories（现为艾伯维）担任高级副总裁兼首席知识产权法律顾问十多年。Ryan Previoly先生于2011年8月至2019年11月担任Applied DNA Sciences，Inc.（纳斯达克：APDN）的董事会成员，并于2015年4月至2020年1月担任BioRestorative Therapies，Inc.（纳斯达克：BRTX）的董事会成员。Ryan博士拥有斯特恩新英格兰大学法学博士学位、纽约州立大学石溪分校口腔生物学和病理学博士学位以及伍斯特学院化学学士学位。他是纽约州律师协会会员，是美国专利商标局的专利从业人员。
- Charles Ryan has served as a member of Polaryx Therapeutics, Inc. Board since January 2026. Dr. Ryan currently serves as President of Quince Therapeutics, Inc. (Nasdaq: QNCX), a late stage biotechnology company, and Chief Executive Officer of their subsidiary company, Quince Therapeutics S.p.A, positions he has held since September 2023. Prior to joining Quince, Dr. Ryan served as a life sciences consultant from November 2022 to September 2023 working with a start up company to identify a regulatory path for a novel device. Dr. Ryan served as President, Chief Executive Officer and Chairman of the Board of Travecta Therapeutics, Pte Ltd., a biopharmaceutical company, from May 2021 to October 2022, and Chief Executive Officer and Director of Neurotrope, Inc. (Nasdaq: NTRP), a biopharmaceutical company, from December 2017 to December 2020 and President and Chief Executive Officer of Orthobond Corporation from October 2016 to February 2018. Earlier in his career, Dr. Ryan served as Senior Vice President and Chief Intellectual Property Counsel at Forest Laboratories (now AbbVie) for more than ten years. Mr. Ryan previoly served on the board of directors of Applied DNA Sciences, Inc. (Nasdaq: APDN) from Augt 2011 to November 2019 and BioRestorative Therapies, Inc. (Nasdaq: BRTX) from April 2015 to January 2020.Dr. Ryan holds a J.D. from stern New England University, a Ph.D. in Oral Biology and Pathology from the State University of New York at Stony Brook, and a B.A. in Chemistry from The College of Wooster. He is a member of the New York State Bar and is a patent practitioner of the U.S. Patent and Trademark Office.
- Charles Ryan
Charles Ryan，曾担任Neurotrope, Inc.公司的首席执行官兼董事，该公司是一家临床阶段的生物制药公司，为神经退行性疾病和发育障碍开发靶向、新型再生疗法。在此之前，他曾在Forest Laboratories（现为艾伯维）担任高级副总裁兼首席知识产权法律顾问超过10年，在那里他管理了跨越CNS、心血管、胃肠道、呼吸和抗感染治疗领域的多个知识产权产业。他还与商业和开发团队，以及Forest的商业开发团队密切合作。Ryan博士拥有Western New England大学的法学博士学位、石溪大学的口腔生物学和病理学博士学位以及伍斯特学院的化学学士学位。他是纽约州律师协会会员，是美国专利商标局的专利从业人员。
Charles Ryan,served as Chief Executive Officer and Director of Neurotrope, Inc., a clinical-stage biopharmaceutical company developing targeted, novel regenerative therapeutics for neurodegenerative diseases and developmental disorders. Prior to that, he served as Senior Vice President and Chief Intellectual Property Counsel at Forest Laboratories (now AbbVie) for more than 10 years where he managed several intellectual property estates spanning CNS, cardiovascular, gastrointestinal, respiratory, and anti-infective therapeutic areas. He also worked closely with the commercial and development teams, as well as the business development teams at Forest. Dr. Ryan holds a J.D. from Western New England University, a Ph.D. in Oral Biology and Pathology from Stony Brook University, and a B.A. in Chemistry from The College of Wooster. He is a member of the New York State Bar and is a patent practitioner of the U.S. Patent and Trademark Office.- Charles Ryan，曾担任Neurotrope, Inc.公司的首席执行官兼董事，该公司是一家临床阶段的生物制药公司，为神经退行性疾病和发育障碍开发靶向、新型再生疗法。在此之前，他曾在Forest Laboratories（现为艾伯维）担任高级副总裁兼首席知识产权法律顾问超过10年，在那里他管理了跨越CNS、心血管、胃肠道、呼吸和抗感染治疗领域的多个知识产权产业。他还与商业和开发团队，以及Forest的商业开发团队密切合作。Ryan博士拥有Western New England大学的法学博士学位、石溪大学的口腔生物学和病理学博士学位以及伍斯特学院的化学学士学位。他是纽约州律师协会会员，是美国专利商标局的专利从业人员。
- Charles Ryan,served as Chief Executive Officer and Director of Neurotrope, Inc., a clinical-stage biopharmaceutical company developing targeted, novel regenerative therapeutics for neurodegenerative diseases and developmental disorders. Prior to that, he served as Senior Vice President and Chief Intellectual Property Counsel at Forest Laboratories (now AbbVie) for more than 10 years where he managed several intellectual property estates spanning CNS, cardiovascular, gastrointestinal, respiratory, and anti-infective therapeutic areas. He also worked closely with the commercial and development teams, as well as the business development teams at Forest. Dr. Ryan holds a J.D. from Western New England University, a Ph.D. in Oral Biology and Pathology from Stony Brook University, and a B.A. in Chemistry from The College of Wooster. He is a member of the New York State Bar and is a patent practitioner of the U.S. Patent and Trademark Office.
- Brendan Hannah
Brendan Hannah，于2021年11月至2022年5月担任生物制药公司Novosteo Inc.的首席运营官。此前，自2019年1月至2021年10月，Hannah先生担任生物制药公司Neuroptika，Inc.的首席商务官，并于2017年1月至2020年3月担任生物制药公司Geom Therapeutics的运营和战略副总裁。Hannah先生拥有加州大学洛杉矶安德森管理学院的工商管理硕士学位和科罗拉多学院的经济学学士学位。
Brendan Hannah,served as the Chief Operating Officer of Novosteo Inc., a biopharmaceutical company, from November 2021 to May 2022. Previously, from January 2019 to October 2021, Mr. Hannah was the Chief Business Officer of Neuroptika, Inc., a biopharmaceutical company, and from January 2017 to March 2020, the Vice President of Operations and Strategy of Geom Therapeutics, a biopharmaceutical company. Mr. Hannah holds an M.B.A. from the University of California, Los Angeles Anderson School of Management and a B.A. in Economics from Colorado College.- Brendan Hannah，于2021年11月至2022年5月担任生物制药公司Novosteo Inc.的首席运营官。此前，自2019年1月至2021年10月，Hannah先生担任生物制药公司Neuroptika，Inc.的首席商务官，并于2017年1月至2020年3月担任生物制药公司Geom Therapeutics的运营和战略副总裁。Hannah先生拥有加州大学洛杉矶安德森管理学院的工商管理硕士学位和科罗拉多学院的经济学学士学位。
- Brendan Hannah,served as the Chief Operating Officer of Novosteo Inc., a biopharmaceutical company, from November 2021 to May 2022. Previously, from January 2019 to October 2021, Mr. Hannah was the Chief Business Officer of Neuroptika, Inc., a biopharmaceutical company, and from January 2017 to March 2020, the Vice President of Operations and Strategy of Geom Therapeutics, a biopharmaceutical company. Mr. Hannah holds an M.B.A. from the University of California, Los Angeles Anderson School of Management and a B.A. in Economics from Colorado College.